Trump administration names permanent FDA division leaders
The drumbeat of change within the Food and Drug Administration has reached a fever pitch. On Tuesday, the administration announced the permanent installation of four key leadership roles within the FDA, elevating acting leaders into enduring positions and signaling a strategic shift in how the agency will oversee drugs, vaccines, and tobacco. This is more than a headline—it is a map for veteran entrepreneurs who are navigating regulatory pathways, seeking reliable guidance, and building durable enterprises in a landscape where science, policy, and commerce intersect. At the center of this transition is the nomination of Heidi Overton to lead the FDA, a move that solidifies continuity and expectation for steadier leadership. For veteran founders who have learned to operate under shifting guidelines and evolving federal priorities, the appointment offers a measure of predictability. When regulators present a consistent front, it reduces the cost of uncertainty—the kind of cost that e...